Impax Laboratories Inc (IPXL)

13.45
0.20 1.50
NASDAQ : Health Care
Prev Close 13.25
Open 13.25
Day Low/High 13.15 / 13.80
52 Wk Low/High 27.62 / 50.74
Volume 1.36M
Avg Volume 1.20M
Exchange NASDAQ
Shares Outstanding 73.88M
Market Cap 956.73M
EPS 0.60
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Impax Laboratories Inc. Shareholder Alert: Former SEC Attorney Willie Briscoe And Powers Taylor Investigate Possible Breaches Of Fiduciary Duty By Officers And Directors

Impax Laboratories Inc. Shareholder Alert: Former SEC Attorney Willie Briscoe And Powers Taylor Investigate Possible Breaches Of Fiduciary Duty By Officers And Directors

Former United States Securities and Exchange Commission attorney Willie Briscoe, founder of The Briscoe Law Firm, PLLC, and the securities litigation firm of Powers Taylor LLP announce that a federal class action lawsuit...

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AXE, CECE, EMN, FC, NNI, PDCO, SAH, SAMG, WERN Downgrades: ATW, CERN, IPXL, NVO, OMCL, PHII, PHIIK, PLKI, SVT Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit Against Impax Laboratories Inc. And Encourages Investors With Losses To Contact The Firm

IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit Against Impax Laboratories Inc. And Encourages Investors With Losses To Contact The Firm

Khang & Khang LLP (the "Firm") announces a class action lawsuit against Impax Laboratories Inc.

IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit Against Impax Laboratories Inc. And Encourages Investors With Losses To Contact The Firm

IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit Against Impax Laboratories Inc. And Encourages Investors With Losses To Contact The Firm

Khang & Khang LLP (the "Firm") announces a class action lawsuit against Impax Laboratories Inc.

Rosen Law Firm Files Securities Class Action Lawsuit Against Impax Laboratories, Inc. - IPXL

Rosen Law Firm Files Securities Class Action Lawsuit Against Impax Laboratories, Inc. - IPXL

Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of Impax Laboratories, Inc.

In Case You Missed It Nov. 9: Goldman, GoPro, GTT and the GOP

In Case You Missed It Nov. 9: Goldman, GoPro, GTT and the GOP

Impax is Slowly Stealing Market Share from Mylan; Goldman Names New Partners; Twinkie Maker Hostess Brands Preps for Its Next Chapter; and more from The Street.

Rosen Law Firm Continues To Investigate Securities Claims Against Impax Laboratories Inc. To Recover Investor Losses - IPXL

Rosen Law Firm Continues To Investigate Securities Claims Against Impax Laboratories Inc. To Recover Investor Losses - IPXL

Rosen Law Firm, a global investor rights law firm, announces that it continues to investigate potential securities claims on behalf of shareholders of Impax Laboratories Inc.

Glancy Prongay & Murray Commences Investigation On Behalf Of Impax Laboratories Inc. Investors Concerning Recent Revelations Regarding An Alleged Illegal Conspiracy To Fix Drug Prices

Glancy Prongay & Murray Commences Investigation On Behalf Of Impax Laboratories Inc. Investors Concerning Recent Revelations Regarding An Alleged Illegal Conspiracy To Fix Drug Prices

Glancy Prongay & Murray LLP ("GPM") announces an investigation on behalf of Impax Laboratories Inc.

Impax is Slowly Stealing Market Share from Mylan, but Manufacturing Could Get in the Way

Impax is Slowly Stealing Market Share from Mylan, but Manufacturing Could Get in the Way

Impax makes a generic version of Adrenaclick, a competitor to Mylan's EpiPen.

Analysts' Actions -- Biogen, GoPro, L Brands, Time Warner and More

Analysts' Actions -- Biogen, GoPro, L Brands, Time Warner and More

Here are Monday's top research calls, including upgrades for Biogen and Time Warner, and downgrades for GoPro and L Brands.

After Big Drop in Generics, Ride the Rebound

After Big Drop in Generics, Ride the Rebound

Investors have a buying opportunity because the damage by any criminal charges is far less than what is likely to be inflicted by the feds.

Generics Hit by Report on Pending DOJ Price Fixing Charges

Generics Hit by Report on Pending DOJ Price Fixing Charges

The DOJ's investigation has been under way for at least two years and a number of companies have reported receiving subpoenas related to the investigation.

Health Sector Down As Report of Industry Price Collusion Surfaces

Health Sector Down As Report of Industry Price Collusion Surfaces

The healthcare sector was dragged down by reports of price collusion and worse-than-expected third-quarter profits.

Media Alert: Experts Available Now And At American College Of Allergy, Asthma And Immunology (ACAAI) Scientific Meeting

Media Alert: Experts Available Now And At American College Of Allergy, Asthma And Immunology (ACAAI) Scientific Meeting

FDA Approved, Low-cost Treatment for Patients who Require Epinephrine Auto-Injection, Available Now

Teva Divests More Assets to Win EC Approval for Allergan Generics Deal

Teva Divests More Assets to Win EC Approval for Allergan Generics Deal

India drugmaker Intas will pay about $770 million for the UK and Ireland generics assets.